Telacebec treatment for Buruli ulcer in adults
Part of Infections, Skin clinical trials.
This trial tests whether the drug telacebec can treat Buruli ulcer, a skin infection caused by bacteria. It aims to find a simpler, shorter treatment for people with mild to moderate lesions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed Buruli ulcer diagnosed by a doctor, with one or more sores smaller than 4 inches across.
- You must have a positive lab test (PCR or culture) showing the bacteria that causes Buruli ulcer.
- You must be 18 years or older.
- You cannot have had Buruli ulcer treatment in the last year.
- You cannot plan to have surgery to cut out the ulcer during the study (normal wound care is okay).
- If you are 60 or older, you must weigh less than 85 kg (about 187 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of antibiotics (Arm D) against the standard treatment for people with a difficult-to-treat lung infection called Mycobacterium abscessus. It is for adults and teens aged 12 and older, including those with cystic fibrosis.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial studies a specific drug combination (BPaLM) for adults with drug-resistant pulmonary (lung) tuberculosis. If you qualify, the goal is to see whether this treatment is effective and safe for your type of infection.
This study tests an investigational drug called MB-001 for people with moderate to severe ulcerative colitis who have already tried standard treatments without success. It aims to see if the drug is safe and helps control inflammation.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
Hear when a new Buruli Ulcer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.